An observational study in Embolic Stroke of Undetermined Source, sponsored by Inha University Hospital. Recruiting at 5 sites in South Korea. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.
Sponsored by Inha University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Ischemic Stroke with a site in Korea, Republic of — 16 open to participants now, 20 under way, 7 of them phase 3. Ischemic Stroke · Korea, Republic of.
Among the 88 studies in Ischemic Stroke with a site in Korea, Republic of, this one is the 25th largest by planned enrollment of the 27 observational ones that give a count, is one of 4 that started in 2025, is one of 27 observational ones, reaches primary completion later than 8 of the 19 other live ones, and was the 83rd registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →16 of the 88 studies in Ischemic Stroke with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Minyoul Baik · Sites in Korea, Republic of
Ages 19+
Sungkyunkwan University · Sites in Korea, Republic of
Ages 19+
Yonsei University · Sites in Korea, Republic of
Ages 19+
Hanyang University Guri Hospital · Sites in Korea, Republic of
Ages 19+
Corxel Pharmaceuticals · Sites in Korea, Republic of, United States, Belgium and 18 more countries
Ages 18–90
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 20 · Phase 4 12
First in 2003; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 92 is below the median of 300 across 773 observational studies indexed under Ischemic Stroke.
Median enrollment 198 across the 60 interventional studies, 474 across the 27 observational. Of the 52 that completed or were terminated, 13 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
37 of 88 have an industry lead sponsor. The 10 most frequent:
Inha University Hospital is the lead sponsor of 37 studies on the registry; 8 are open to participants now.
Inha University Hospital has 1 study filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
6 of the studies in Ischemic Stroke with a site in Korea, Republic of that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06660719Phase 3Shin Poong Pharmaceutical Co. Ltd.Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care | 2027-03-30 |
| NCT07687706Phase 3Hanyang University Guri HospitalTegoprazan for Prevention of Gastrointestinal Complication in Ischemic Stroke Patients on Antiplatelet Therapy (TegoStroke) | 2027-06 |
| NCT06770426Phase 3Yonsei UniversityCompARing Between CO2 Phenylephrine and Phenylephrine Only Treatment in Patients With proGrEssing Cerebral infarctioN | 2027-09 |
| NCT06752096Navigantis Inc.Robot-Assisted Neurovascular Intervention | 2026-12-01 |
| NCT07156955Sungkyunkwan UniversityProprioceptive Error Correction for Post-Stroke Upper Limb Rehabilitation | 2026-12-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 88 studies in Ischemic Stroke with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study investigates patients with Embolic Stroke of Undetermined Source (ESUS) who have received an Implantable Cardiac Monitor (ICM). The main purpose is to evaluate the predictive value of an Artificial Intelligence ECG analysis tool, named SmartECG-AF.
Participants will be classified into two groups based on the AI analysis: a "High Risk" group and a "Low to Intermediate Risk" (control) group. The study aims to compare the incidence rate of atrial fibrillation (AF) events over time between these two groups. Additionally, the study will analyze the relationship between the AI-predicted risk levels and the occurrence of major cardiovascular events during the follow-up period.
Embolic Stroke of Undetermined Source (ESUS) accounts for a significant proportion of ischemic strokes, and occult Atrial Fibrillation (AF) is considered a major etiology. While Implantable Cardiac Monitors (ICMs) are the gold standard for long-term rhythm monitoring, identifying patients at the highest risk for AF remains a clinical challenge.
This multicenter, prospective study aims to validate the clinical utility of an artificial intelligence-based electrocardiogram analysis algorithm, "SmartECG-AF," in this specific population. The algorithm analyzes 12-lead ECGs recorded during sinus rhythm to detect subtle signs of electrical remodeling associated with paroxysmal AF.
Enrolled patients with ESUS who have undergone ICM implantation will have their baseline ECGs analyzed by the SmartECG-AF algorithm. Based on the AI-generated probability score, patients will be stratified into a "High Risk" group and a "Low to Intermediate Risk" group. The study will longitudinally track these patients to compare the time-to-event for ICM-detected AF between the two groups. Additionally, the study will evaluate the correlation between the AI risk score and the incidence of Major Adverse Cardiovascular Events (MACE), providing evidence for AI-guided risk stratification in cryptogenic stroke management.
Patients diagnosed with Embolic Stroke of Undetermined Source (ESUS) aged 30 years or older who have received or are scheduled to receive an Implantable Cardiac Monitor (ICM). Participants are recruited from five tertiary referral hospitals in South Korea (Inha University Hospital, Jeju National University Hospital, Korea University Guro Hospital, Korea University Ansan Hospital, and Ajou University Hospital).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients classified as having a high risk of atrial fibrillation by the SmartECG-AF AI algorithm.
Patients classified as having a low to intermediate risk of atrial fibrillation by the SmartECG-AF AI algorithm.
Incidence of Atrial Fibrillation (Time-to-Event)
Comparison of the cumulative incidence rate of atrial fibrillation (AF) events between the High Risk group and the Low to Intermediate Risk group (classified by SmartECG-AF). AF occurrence is confirmed by reviewing data recorded on the Implantable Cardiac Monitor (ICM).
Time frame: Up to 12 months
Incidence of Major Adverse Cardiovascular Events (MACE)
Evaluation of the composite rate of major clinical events including recurrent stroke, hospitalization for heart failure, myocardial infarction, and all-cause death (cardiovascular and non-cardiovascular). The study will analyze the correlation between the occurrence of these events and the AI-predicted risk levels.
Time frame: Up to 12 months
Plan to share: No — Individual participant data will not be shared to protect participant privacy and confidentiality. The informed consent form signed by participants does not include authorization for the release of individual raw data to third parties.
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for May 2027, 18 months after the start.
Of 397 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 18 months is below that.
Counting every sponsor, half of 439 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Inha University Hospital